Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18706169 | 0.91 | P2RY14 (0.40) | P2RY14 | |
| SCHEMBL18706006 | 0.90 | POLB (0.37) | CNR1HSD11B1P2RY14ANO1POLB | |
| SCHEMBL18706493 | 0.90 | CNR2 (0.42) | CNR1HSD11B1ANO1MAPT | |
| SCHEMBL18706206 | 0.90 | P2RY14 (0.42) | P2RY14PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL18706466 | 0.89 | HSD11B1 (0.36) | CNR1HSD11B1P2RY14ANO1 | |
| SCHEMBL18706017 | 0.88 | P2RY14 (0.39) | CNR1HSD11B1P2RY14PRKAB2PRKAG1 | |
| SCHEMBL18706262 | 0.88 | HPGDS (0.40) | P2RY14TP53POLB | |
| SCHEMBL18706001 | 0.88 | P2RY14 (0.53) | P2RY14 | |
| SCHEMBL18706194 | 0.87 | P2RY14 (0.37) | CNR1HSD11B1P2RY14PRKAB2PRKAG1 | |
| SCHEMBL18706302 | 0.87 | XDH (0.41) | P2RY14PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137566-B | Triazole derivatives | 豪夫迈·罗氏有限公司 | 2021-05-25 | — | — | CN | claimed |
| EP-3359537-B1 | TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | claimed |
| US-10273217-B2 | Triazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-04-30 | — | — | US | claimed |
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | claimed |
| WO-2017060202-A1 | TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | claimed |
| CN-108137566-B | Triazole derivatives | 豪夫迈·罗氏有限公司 | 2021-05-25 | — | — | CN | disclosed |
| EP-3359537-B1 | TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | disclosed |
| EP-3359537-B1 | TRIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-10273217-B2 | Triazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273217-B2 | Triazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-08-23 | — | — | US | disclosed |
| WO-2017060202-A1 | TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017060202-A1 | TRIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237401-A1 | TRIAZOLE DERIVATIVES | MC2R, MC3R, OXTR | CNR1 120/4885HSD11B1 104/4885P2RY14 3532/4885 |
| US-10273217-B2 | Triazole derivatives | MC2R, MC3R, OXTR | CNR1 120/4885HSD11B1 104/4885P2RY14 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.